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Abstract
Background: The prediction of infection and its severity remains difficult in the critically ill. A novel, simple biomarker
derived from five blood-cell derived parameters that characterize the innate immune response in routine blood samples,
the intensive care infection score (ICIS), could be helpful in this respect. We therefore compared the predictive value of
the ICIS with that of the white blood cell count (WBC), C-reactive protein (CRP) and procalcitonin (PCT) for infection and
its severity in critically ill patients.
Methods: We performed a multicenter, cluster-randomized, crossover study in critically ill patients between January
2013 and September 2014. Patients with a suspected infection for which blood cultures were taken by the attending
intensivist were included. Blood was taken at the same time for WBC, ICIS, CRP and PCT measurements in the control
study periods. Results of imaging and cultures were collected. Patients were divided into groups of increasing likelihood
of infection and invasiveness: group 1 without infection or with possible infection irrespective of cultures, group 2 with
probable or microbiologically proven local infection without blood stream infection (BSI) and group 3 with BSI
irrespective of local infection. Septic shock was assessed.
Results: In total, 301 patients were enrolled. CRP, PCT and ICIS were higher in groups 2 and 3 than group 1. The area
under the receiver operating characteristic curve (AUROC) for the prediction of infection was 0.70 for CRP, 0.71 for PCT
and 0.73 for ICIS (P < 0.001). For the prediction of septic shock the AUROC was 0.73 for CRP, 0.85 for PCT and 0.76 for
ICIS. These AUROC did not differ from each other.
Conclusion: The data suggest that the ICIS is potentially useful for the prediction of infection and its severity in critically
ill patients, non-inferiorly to CRP and PCT. In contrast to CRP and PCT, the ICIS can be determined routinely without
extra blood sampling and lower costs, yielding results within 15 minutes.
Trial registration: ClinicalTrials.gov identifier: ID NCT01847079. Registered on 24 April 2013.
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Background
Infection is probable or can be proven in approximately
50 % of critically ill patients with suspected infection
[1, 2]. This could lead potentially to overtreatment with
empiric antibiotics [1, 2]. Moreover, infection diagnostics
are often delayed because it takes 48 h at the minimum
for cultures to become positive and thereby to prove a
clinically suspected infection. Hence, there is a continuing
need for fast and accurate biomarkers of infection, which
may help to predict infection, its invasiveness and severity,
and may guide empiric antibiotic treatment in the future
[3]. We believe that prediction of infection is more helpful
in patient management than prediction of sepsis, because
the majority of critically ill patients have two or more cri-
teria of the systemic inflammatory response syndrome
(SIRS) as criteria for sepsis, irrespective of infection.
Commonly applied biomarkers include C-reactive pro-
tein (CRP) and procalcitonin (PCT), but predictive values
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vary among studies [3–11]. A new biomarker is the inten-
sive care infection score (ICIS), which is composed of five
blood-cell-derived parameters characterizing the early in-
nate immune response and is routinely obtainable in
blood samples sent to the laboratory for cell counts. The
ICIS has been retrospectively evaluated in two pilot stud-
ies of 70 and 172 patients, respectively, suggesting it has
potential predictive value for infection [12, 13].
We therefore performed a prospective study on the
predictive value of ICIS for probable or proven infec-
tion in critically ill patients with suspected infection,
and compared its performance with that of the white
blood cell count (WBC), CRP and PCT levels. We hy-
pothesized that in the critically ill patient with sus-
pected infection the diagnostic accuracy of the simply
obtainable ICIS is at least equivalent in this respect to
WBC, CRP and PCT, without requiring extra blood
sampling.
Methods
Study design and patients
The ICIS study is an add-on non-interventional study of
patients who had been enrolled into a prospective, cluster-
randomized, crossover trial, involving both intensive care
units (ICUs) of the Erasmus Medical Center Rotterdam
and both ICUs of the Maasstad hospital Rotterdam. The
ICUs were stratified and randomized by treatment regi-
men into a control group (standard of care) and an inter-
vention group. In the intervention arm, blood culturing
for a suspected infection was guided by PCT measure-
ments. The acronym for PCT-guided blood culturing in
the intensive care, ProBIC, was used for this study and re-
sults will be reported later. The trial was conducted be-
tween January 2013 and September 2014. The ICU of the
Erasmus Medical Center is a tertiary care mixed medical-
surgical ICU with approximately 2000 admissions per year.
The ICU of the Maasstad hospital is a secondary care
mixed medical-surgical ICU with 1200 admissions per year.
The trial was conducted in accordance with the ethical
principles decreed by the Declaration of Helsinki and in
compliance with International Conference on Harmoniza-
tion Good Clinical Practice Guidelines. The institutional
review board (IRB) or the independent medical ethical
committee at each of the investigational centers (Medisch
Ethische commissie Maasstad ziekenhuis, Rotterdam,
Nederland and Medisch Ethische commissie Erasmus
Medisch Centrum, Rotterdam, Nederland) reviewed and
approved the protocol, amendments and informed con-
sent document. The medical ethical committee of the
Erasmus Medical Center finally approved the study (MEC
2011-505). The trial was registered at ClinicalTrial.gov
(protocol ID NCT01847079) on 24 April 2013. All pa-
tients or their proxy provided written informed consent
prior to study inclusion, at ICU admission.
Inclusion criteria were age above 18 and below 80 years
and the clinical suspicion of infection, for which the at-
tending intensivist established a medical need for blood
culture. Suspicion of infection included but was not
limited to increased body temperature above 38.3 °C
(tympanic temperature), chills, progressive leukocytosis,
increased CRP, increasing consolidation on chest radiog-
raphy or other imaging of potential infection sources. It
was possible for each patient to be included more than
once, but in the current study we only analyzed the first
time that blood was sampled for culture. Patients were
excluded if they were pregnant, had neutropenia (defined
as leukocyte count less than 0.5 × 109/L), used immunosup-
pressive or immunostimulatory therapy, or had a predeter-
mined illness with death expected within 24 h. Patients
were not included if blood cultures were performed as part
of a standard protocol (such as patients with veno-venous
or veno-arterial extracorporeal membrane oxygenation
(ECMO)) or were performed to check the effectiveness of
treatment (such as in endocarditis), unless the blood cul-
ture was done because of suspicion of infection. The ICUs
switched the allocated regimen every 3 months, so that
there were six 3-month episodes of standard care in which
774 patients were eligible for inclusion, and 473 patients
were excluded (5 patients who were ≤18 years of age; 63
with neutropenia (<0.5 × 104/L); 35 with uncontrolled ma-
lignancy; 256 on immunosuppressive medication; 22 who
were expected to die within 24 h; and 92 without informed
consent). Data for the ICIS study were thus collected in 301
patients in the control arm (six 3-month episodes) of the
ProBIC study.
Study protocol, data collection and assays
Baseline demographic data and clinical variables were re-
corded on the day of inclusion, and included age, sex,
comorbidity, reasons for admission, use of antibiotics in-
cluding selective decontamination of the digestive tract
(SDD), antifungal treatment, steroids, immunosuppressive
medication, immune status and recent surgery. The treat-
ment received during ICU stay was also recorded and in-
cluded mechanical ventilation, renal replacement therapy,
total parenteral nutrition, arterial and central venous cath-
eters, and the use of vasopressor or inotropic medication.
The acute physiology and chronic health evaluation II
(APACHE II) and the sequential organ failure assessment
(SOFA) score were recorded at admission. The length of
ICU and hospital stay and vital outcomes were recorded
for up to 90 days after inclusion.
At the same time that blood was taken for culture, blood
samples were taken for determination of WBC, CRP, PCT,
and ICIS (day 0). Blood for similar measurements (except
for PCT) was taken in the morning on the two following
days (days 1 and 2). Treating physicians and investigators
were blinded to the PCT and ICIS measurement results.
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Also the outcome adjudicators that decided presence or
absence of infection were blinded to the biomarker results.
Two sets of blood cultures were taken and directly sent to
the department of medical microbiology. The set taken for
blood culture consisted of one aerobic and one anaerobic
bottle (BD Bactec™, Franklin Lakes, NJ, USA), which con-
tain resin to enhance recovery of organisms. The samples
were incubated for a 7-day period in an automatic analyzer
(BD Bactec™) that automatically demonstrates the time to
positive blood culture in the case of positive bacterial or
fungal growth. Gram strains were performed, and the or-
ganisms were cultured on agar plates after identification of
growth using the VITEK® 2 (Biomerieux, Marcy l’Etoile,
France).
Blood for the WBC and ICIS measurement was obtained
in a K3EDTA tube. Both the WBC and ICIS parameters
were measured on a modified fluorescence flow hematology
analyzer with fully automated gating (Sysmex, Kobe, Japan)
[14]. The ICIS was measured promptly after collection but
within a maximum of 24 h. The ICIS score is composed of
five blood-cell-derived parameters that characterize the
innate immune response [15–19]. The five parameters
include the mean fluorescence intensity of mature (seg-
mented) neutrophils, the difference in hemoglobin con-
centration between newly formed and mature red blood
cells, the total segmented neutrophil count, the anti-
body secreting lymphocytes, and the accurate immature
granulocytes count, as previously described [12]. Each
parameter is available from a standard routine method
and can be measured within 1 minute without sample
preparation on a modified fluorescence flow hematology
analyzer with fully automated gating (Symex) [12]. The
methodology is based on routine hematology fluorescence
flow cytometry using different fluorescence reagents for
mainly nucleic acids, and specifically designed blood cell
membrane surfactant reagents generating information
about cell shape and the formation of bioactive lipids from
cell membranes [12]. Side and forward scatter light are
used to determine the intracellular structure and size of
blood cells [12]. By adding all weighting values for all five
parameter components, the maximum possible ICIS is 20.
Serum CRP (turbidimetric assay) and PCT (electrochemi-
luminescence BRAHMS immunoassay) measurements
were routinely performed using a Cobas 8000 platform
(Roche, Almere, Netherlands). Blood for PCT measure-
ment was sampled in a z serum clot activator tube.
Definitions
After completion of the study, the investigators decided
whether an infection was present from days 0–2, on the
basis of the available imaging and culture results. The
outcome adjudicators were blinded to all biomarkers.
Source and likelihood of infection were based on criteria
defined at the International Sepsis Forum Consensus
Conference [20]. Culture results were analyzed within a
48-h window from before and after taking blood cul-
tures. The causative microorganisms were recorded. BSI
was defined as a positive blood culture with a recognized
pathogen except for skin contaminants [20, 21]. In the case
of skin contaminants, BSI was identified if at least two
blood cultures drawn on separate locations were positive
[20, 21]. Patients were divided into groups according to
increasing likelihood of infection and invasiveness of asso-
ciated microorganisms that was suggestive of increasing se-
verity: group 1 without infection or with possible infection
irrespective of cultures; group 2 with probable (irrespective
of cultures) or proven local infection (with positive cultures
of a causative microorganism) without BSI; and group 3
with BSI irrespective of local infection. SIRS was defined as
two or more of the following criteria: (1) body temperature
>38 °C or <36 °C; (2) WBC (>10,000/μL), leukopenia
(<4,000/μL), or >10 % bands; (3) heart rate >90 beats/mi-
nute; and (4) respiratory rate >20 breaths/minute or mech-
anical ventilation, for values at day 0. When SIRS and a
probable/proven infection (groups 2 or 3) were present,
patients were classified as having sepsis. Shock was de-
fined as acute circulatory failure characterized by per-
sistent systolic arterial pressure <90 mm Hg or mean
arterial pressure (MAP) <70 mm Hg for at least 1 h
despite adequate fluid resuscitation or requirement of
vasopressor support to maintain MAP, at day 0. In the
presence of sepsis, shock was defined as septic shock.
Statistical analysis
This was performed using SPSS version 23 (SPSS inc., Chi-
cago IL, USA) and using R package. Data are expressed as
median (interquartile range) or as number of patients (per-
centage) where appropriate. Most data were distributed
non-normally (Kolmogorov-Smirnov test P < 0.05). Group
(>2) differences were evaluated using the Kruskal-Wallis
test or chi-square (X2) test, for continuous and categorical
data, respectively. The Mann-Whitney U test and Fisher
exact test were used to compare two groups. To evaluate
predictive values we calculated the areas under the re-
ceiver operating characteristic curves (AUROC) for day 0
values. For the predictive values of sepsis and septic shock
we used the values for day 0. We consider an AUROC
>0.70 as clinically relevant [22]. The optimum cutoff value
was calculated on the basis of the highest sensitivity and
specificity combined (Youden index). Positive and negative
predictive values were calculated. To correct for multiple
testing we set the level of statistical evidence at P ≤ 0.01.
Exact P values >0.001 are given.
Results
Patient characteristics
Table 1 describes the baseline characteristics of the 301
patients enrolled: 149 patients (group 1) had no infection
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and 152 patients (groups 2 + 3) had a probable or proven
infection. Patients with a probable or proven infection were
older and more often had a history of cancer, cardiac dis-
ease or gastrointestinal problems. Mechanical ventilation or
renal replacement therapy was more often used in patients
with a probable or proven infection. All patients with a
probable or proven infection were on antibiotics. No differ-
ence was seen in 28-day or 90-day mortality or in the
length of ICU or hospital stay.
Source of infection and microbial species
The abdomen and lungs were the most frequent source of
infection (Table 2). Gram-positive pathogens were mostly
cultured, followed by Gram-negative pathogens, fungi and
viruses (Table 2).
Biomarkers
Table 2 shows the infection markers according to inva-
siveness of infection. Most patients had SIRS on day 0,
so that the patients with infection in groups 2 and 3 had
mostly sepsis. CRP, PCT and ICIS were increased on
days 0–2 in patients with infection as compared to those
without infection. In contrast to PCT, there was no dif-
ference in CRP and ICIS between groups 2 and 3. The
CRP, PCT and ICIS were increased in patients with sep-
tic shock (Table 3).
Predictive values
The AUROC for the prediction of infection (groups 2 + 3
vs group 1) on day 0 was similar for CRP, PCT and ICIS
(Table 4, Fig. 1). At a cutoff ≥7, the positive predictive value
of ICIS was >80 % and at a cutoff ≤1 the negative predictive
value of ICIS was >80 %. Otherwise, the AUROC for ICIS
did not differ from that of any other biomarkers, including
PCT, expect for that of WBC (P < 0.001). The highest
AUROC for the prediction of septic shock was for PCT
(AUROC 0.85, P < 0.001), but this was not significantly dif-
ferent to the AUROC for ICIS (AUROC 0.76, P < 0.001),
whereas the AUROC for CRP was 0.73 (P < 0.001) and the
AUROC for WBC was 0.53 (P = 0.68) (Fig. 2).
Discussion
This study evaluated the predictive values of ICIS to dis-
criminate between non-infectious systemic inflammation
and infection (mostly sepsis) in critically ill patients with
a suspicion of infection. The data suggest that ICIS is a
useful marker to predict probable or proven infection
and its severity and is non-inferior in this respect to
CRP and PCT.
In the current study the frequency of probable or
proven infection was 56 % of patients when an infection
was suspected, which is comparable with the reported
frequency of 51–58 % in large studies on the epidemi-
ology of sepsis in the ICU [23]. The lung and abdomen
were the most common origin of sepsis, followed by in-
fections of soft tissues, as described before [24]. A large
recently performed study showed that Gram-negative
bacteria were isolated in 62 % of patients with sepsis
Table 1 Baseline demographic and clinical characteristics
Group 1 Groups 2 + 3 P
(n = 149) (n = 152)
Age (years) 57 (24) 62 (19) 0.01
Gender (male) 100 (67) 105 (69) 0.72
APACHE II score 22 (10) 22 (8) 0.92
APACHE IV score 63 (38) 60 (34) 0.49
SOFA score 7 (7) 8 (6) 0.06
Comorbidity
Neurologic 39 (26) 41 (27) 0.88
Cardiac 40 (27) 58 (38) 0.04
Pulmonary 28 (19) 38 (25) 0.25
Gastrointestinal 39 (26) 55 (36) 0.05
Renal 15 (10) 24 (16) 0.14
DM II 22 (15) 33 (22) 0.13
Cancer 22 (15) 46 (30) 0.002
Autoimmune 7 (5) 8 (5) 0.97
Reasons for ICU admission <0.001
Suspected infection 23 (15) 69 (45)
Respiratory failure 24 (16) 33 (22)
Renal failure 0 (0) 1 (1)
Liver failure 5 (3) 3 (2)
Neurology 31 (21) 8 (5)
CPR 9 (6) 5 (3)
Shock 10 (7) 3 (2)
Trauma 13 (9) 5 (3)
Postoperative 34 (23) 25 (17)
Treatment on ICU
Antibiotics 140 (94) 152 (100) 0.02
Norepinephrine 109 (73) 128 (84) 0.03
Dobutamine 18 (12) 17 (11) 0.80
TPN 39 (26) 50 (33) 0.20
Mechanical ventilation 133 (89) 125 (82) 0.06
Renal replacement therapy 15 (10) 52 (34) <0.001
Length of ICU stay (days) 9 (17) 11 (17) 0.49
Length of hospital stay (days) 22 (34) 26 (36) 0.13
Mortality day 28 42 (28) 58 (38) 0.09
Mortality day 90 98 (36) 68 (45) 0.13
Numbers (percentage) or median (interquartile range), where appropriate.
Abbreviations: APACHE II acute physiology and chronic health evaluation II,
CPR cardiopulmonary resuscitation, DM II diabetes mellitus type II, ECMO
extracorporeal membrane oxygenation, SOFA sequential organ failure
assessment score, TPN total parenteral nutrition
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who had positive cultures, Gram-positive bacteria in
47 %, and fungi in 19 % [23]. The results are in contrast
with our study, which suggests that Gram-positive isolates
are most likely to cause infection. The difference can be
explained by the fact that we use SDD in our ICUs, which
is known to eliminate Gram-negative bacteria and fungi
from the digestive tract [25]. Blood cultures are typically
positive in approximately one third of the patients with
sepsis, in line with the incidence of 20 % in this study [24].
The overall ICU and hospital mortality rates were 28 and
37 %, respectively. The results are comparable with the re-
ported rates in a European multicenter study of critically
ill patients with sepsis [26].
In the current study the predictive values of WBC and
CRP for infection and sepsis are comparable with those
identified in previous studies, in which a low AUROC of
0.55–0.66 for WBC (sensitivity 65–91 %; specificity 35–
54 %) and an intermediate AUROC of 0.64–0.77 for
CRP (sensitivity 82–100 %; specificity 40–64 %) was re-
ported [4, 5, 10, 11]. Large reviews report an AUROC of
0.78–0.81 for PCT (sensitivity 42–100 %; specificity 48–
100 %), comparable to our study [7, 9]. The reported
predictive value of ICIS in this study is lower compared
with two previous studies, in which AUROC of 0.79
(sensitivity 70 %; specificity 79 %) and 0.85 (sensitivity
80 %; specificity 75 %) were reported, respectively [12, 13].
Both studies investigated a relatively small number of pa-
tients or investigated postoperative critically ill patients
only [12, 13]. They were pilot studies to define the cutoff
values of ICIS as a marker of infection in critically ill
patients and recommended determination of the suit-
ability and effectiveness of this score in a prospective
trial [12, 13].
Using ICIS has several advantages over using CRP or
PCT. First, no extra blood needs to be taken since the ICIS
can be measured from the same K3EDTA tube that is used
for the WBC measurement, thereby allowing routine daily
Table 3 Septic shock
No (n = 280) Yes (n = 21) P
Temperature (°C) 38.2 (1.5) 38.2 (1.6) 0.75
Heart rate (beats/minute) 108 (33) 119 (59) 0.04
Respiratory rate (breaths/minute) 28 (15) 29 (13) 0.85
WBC day 0 (109/L) 12.8 (9.5) 12.5 (17.6) 0.68
WBC day 1 (109/L) 12.4 (9.5) 14.1 (20.4) 0.60
WBC day 2 (109/L) 12.5 (9.4) 14.6 (14.4) 0.41
CRP day 0 (mg/L) 107 (144) 234 (182) <0.001
CRP day 1 (mg/L) 124 (147) 327 (160) <0.001
CRP day 2 (mg/L) 107 (144) 244 (205) <0.001
PCT day 0 (μg/L) 1.15 (6.1) 32.2 (94.0) <0.001
ICIS day 0 4 (5) 9 (6) <0.001
ICIS day 1 4 (4) 8 (7) <0.001
ICIS day 2 5 (5) 7 (6) 0.03
Median (interquartile range). Abbreviations: CRP C-reactive protein, ICIS intensive
care infection score, PCT procalcitonin, WBC white blood cells
Table 2 Infection characteristics
Group 1 Group 2 Group 3 P
(n = 149) (n = 91) (n = 61)
Source of infection 0.01
Pulmonary - 44 (48) 15 (25)
Abdominal - 30 (33) 29 (47)
Urogenital - 8 (9) 2 (3)
Neurologic - 2 (2) 2 (3)
Soft tissue/bones - 7 (8) 10 (17)
Blood and catheter - 0 3 (5)
Gram strain 0.01
Gram-negative - 30 (33) 16 (26)
Gram-positive - 27 (30) 36 (59)
Type of microorganism 0.15
Staphylococci - 15 (16) 17 (28)
Streptococci - 12 (13) 19 (31)
Enterobacteriaceae - 26 (29) 15 (25)
Pseudomonas - 4 (4) 1 (2)
Fungi - 12 (13) 6 (10)
Viral - 5 (5) 3 (5)
Biomarkers
SIRS 146 (98) 90 (99) 58 (95) 0.94
Septic shock - 12 (13) 9 (15) 0.78
Temperature (°C) 38.1 (1.5) 38.3 (1.7) 38.0 (1.5) 0.94
Heart rate (beats/minute) 105 (29) 109 (37) 112 (39) 0.15
Respiratory rate
(breaths/minute)
28 (13) 29 (17) 29 (17) 0.61
WBC day 0 (109/L) 12.4 (7.8) 14.4 (12.9) 13.9 (12.2) 0.63
WBC day 1 (109/L) 11.7 (8.1) 13.9 (13.1) 13.4 (11.3) 0.47
WBC day 2 (109/L) 12.1 (7.2) 14.4 (9.8) 14.8 (15.0) 0.19
CRP day 0 (mg/L) 84 (109) 163 (156) 167 (161) <0.001
CRP day 1 (mg/L) 88 (131) 156 (156) 197 (154) <0.001
CRP day 2 (mg/L) 82 (141) 131 (136) 180 (172) <0.001
PCT day 0 (μg/L) 0.65 (2.30) 2.71 (9.88) 4.13 (38.0) <0.001
ICIS day 0 3 (3) 6 (5) 6 (5) <0.001
ICIS day 1 3 (3) 6 (4) 6 (4) <0.001
ICIS day 2 4 (4) 6 (4) 6 (4) <0.001
Numbers (percentage) or median (interquartile range), where appropriate.
Group 1: no infection; Group 2: local infection without blood stream infection;
Group3: blood stream infection. Abbreviations: CRP C-reactive protein, ICIS
intensive care infection score, PCT procalcitonin, SIRS systemic inflammatory
response syndrome, WBC white blood cells
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measurements. Second, lower costs are involved because
the ICIS measurement is performed on the same ma-
chine used for a WBC measurement. The major limita-
tion is that in our study the predictive values of
biomarkers including ICIS was not very high. Never-
theless, a high ICIS increases the likelihood of infection
when suspected and a low ICIS decreases it. This may
help the clinician in ordering extra tests or starting em-
piric antibiotics. The predictive value of ICIS for infec-
tion and septic shock is comparable with that of the
percentage of immature granulocytes as assessed in a
relatively small study in critically ill patients [27]. Both
the percentage of immature granulocytes and ICIS can
be obtained routinely without extra blood sampling or
cost, though the current study focused on the diagnos-
tic accuracy of ICIS and not its feasibility or cost-
effectiveness. For future use the ICIS is expected to
prove more robust.
Conclusions
In conclusion, the present study suggests that ICIS is a
novel and potentially useful predictor of infection and
sepsis in critically ill patients with a suspected infec-
tion. The ICIS score can be collected routinely without
Fig. 1 Area under the receiver operating characteristic curve for the four biomarkers for the prediction of infection: for white blood cell count
(WBC) 0.53, for C-reactive protein (CRP) 0.70, for procalcitonin (PCT) 0.71, and for intensive care infection score (ICIS) 0.73
Table 4 Receiver operating characteristic curve analysis to determine the optimum cutoff value of the different biomarkers on day 0
for the prediction of infection (groups 2 + 3)
Parameters
Biomarkers AUROC (95 % CI) P Cutoff Sensitivity Specificity PPV NPV
WBC (109/L) 0.53 (0.46, 0.60) 0.38 12.9 0.54 0.54 0.55 0.54
CRP (mg/L) 0.70 (0.64, 0.76) <0.001 111 0.65 0.64 0.65 0.64
PCT (μg/L) 0.71 (0.66, 0.77) <0.001 1.41 0.65 0.66 0.66 0.65
ICIS 0.73 (0.67, 0.79) <0.001 5 0.66 0.71 0.70 0.67
Abbreviations: AUROC area under the receiver operating characteristic curve, CI confidence interval, CRP C-reactive protein, ICIS intensive care infection score, PCT
procalcitonin, PPV positive predictive value, NPV negative predictive value, WBC white blood cells. The AUROC for ICIS differed from that for WBC (P < 0.001)
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extra blood sampling and with lower costs, yielding re-
sults within 15 minutes.
Key messages
 The ICIS score is composed of five blood-cell-
derived parameters that characterize the innate
immune response
 The ICIS score is elevated in patients with probable
or proven infection in the critically ill, similar to
CRP and PCT
 The ICIS score is a novel and potentially useful
predictor of infection and sepsis in critically ill
patients
 The ICIS score can be collected routinely without
extra blood sampling and at a lower cost as
compared to CRP and PCT determinations
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